You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

Details for Patent: 10,112,903

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,112,903 protect, and when does it expire?

Patent 10,112,903 protects ARISTADA and ARISTADA INITIO KIT and is included in two NDAs.

This patent has forty-five patent family members in twenty-one countries.

Summary for Patent: 10,112,903

Title:	Heterocyclic compounds for the treatment of neurological and psychological disorders
Abstract:	Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed. ##STR00001##
Inventor(s):	Remenar; Julius F. (Framingham, MA), Blumberg; Laura Cook (Lincoln, MA), Zeidan; Tarek A. (Watertown, MA)
Assignee:	ALKERMES PHARMA IRELAND LIMITED (Dublin, IE)
Application Number:	15/875,478
Patent Claim Types: see list of patent claims	Use; Composition; Compound;

Drugs Protected by US Patent 10,112,903

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-001	Oct 5, 2015		RX	Yes	No	⤷ Sign Up	⤷ Sign Up		Y		TREATMENT OF SCHIZOPHRENIA	⤷ Sign Up
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-002	Oct 5, 2015		RX	Yes	No	⤷ Sign Up	⤷ Sign Up		Y		TREATMENT OF SCHIZOPHRENIA	⤷ Sign Up
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-003	Oct 5, 2015		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up		Y		TREATMENT OF SCHIZOPHRENIA	⤷ Sign Up
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-004	Jun 5, 2017		RX	Yes	No	⤷ Sign Up	⤷ Sign Up		Y		TREATMENT OF SCHIZOPHRENIA	⤷ Sign Up
Alkermes Inc	ARISTADA INITIO KIT	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	209830-001	Jun 29, 2018		RX	Yes	No	⤷ Sign Up	⤷ Sign Up		Y		TREATMENT OF SCHIZOPHRENIA	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 10,112,903

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	077239	⤷ Sign Up
Argentina	109699	⤷ Sign Up
Australia	2010266018	⤷ Sign Up
Australia	2010266040	⤷ Sign Up
Canada	2766033	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.